Physician :: Jane Freedman, MD

Physician Profile

Jane E. Freedman, MD

Academic Appointment:

Professor of Medicine and Pharmacology
Boston University School of Medicine, Boston MA

Medical School:

Tufts University School of Medicine, Boston MA (1989)

Residency:

Massachusetts General Hospital, Boston MA (1991)

Post Residency:

Fellowship in Cardiovascular Disease, Brigham and Women's Hospital, Boston MA (1994)

Board Certification:

Cardiovascular Disease

Special Interest(s):

Cardiovascular Disease

Bio:

Dr. Jane Freedman is currently a Professor of Medicine and Pharmacology at Boston University School of Medicine and attends in the Division of Cardiology. Dr. Freedman graduated from Yale University, Tufts University School of Medicine, and completed residency and cardiology fellowship at the Massachusetts General Hospital and Brigham and Women's Hospital, respectively. Dr. Freedman has received young investigator awards from both the AHA and the ACC, has been elected to the A.S.C.I., and is currently funded by the NIH and industry. Dr. Freedman is an Associate Editor for Circulation, Editor-in-Chief of Cardiovascular Drug Reviews and Research and on the editorial boards of several journals including Circulation Research and Arteriosclerosis, Thrombosis and Vascular Biology. The major research initiatives in Dr. Freedman's laboratory emphasize the regulation of pathways contributing to atherothrombotic disease and how these factors contribute to acute coronary syndromes. A major initiative in the laboratory is examining the role of immunity, infection, and inflammation on atherothrombotic (specifically platelet function) disease through cell culture and animal studies. In addition, Dr. Freedman is funded by the NHLBI to study gene expression in circulating cells (platelets and leukocytes) in the Offspring Cohort at the Framingham Heart Study. Dr. Freedman is also a member of the Framingham SABRe project and her lab is specifically examining the relation of miRNA to cardiovascular disease in several cohorts of the Framingham Heart Study.

Publications:

Vitseva O, Tanriverdi K, Tchkonia T, Kirkland JL, McDonnell M, Apovian CA, Freedman JE, Gokce N. Inducible Toll-like receptor and NF-?B regulatory pathway expression in human adipose tissue. Obesity 2008;16(5):932-7.
Vanichakarn P, Blair, P. Wu C, Freedman, JE, Chakrabarti S. Neutrophil CD40 enhances platelet-mediated inflammation. Thrombosis Research. 2008;122(3):346-58.
Freedman JE. Translational Therapeutics at the Platelet Vascular Interface: Oxidative Stress and Platelets. Arteriosclerosis, Thrombosis, and Vascular Biology. 2008 28(3):s11-6.
Chakrabarti S, Freedman JE. The Effects of Dipyridamole on the Endothelium. Vascular Pharmacology. 2008;48(4-6):143-9.
Blair PS, Rex S, Vitseva O, Beaulieu L, Tanriverdi K, Chakrabarti S, Hayashi C, Genco CA, Iafrati M, Freedman, JE. Stimulation of Toll-like Receptor 2 in Human Platelets Induces a Thrombo-Inflammatory Response Through Activation of Phosphoinositide 3-Kinase. Circulation Research. 104(3):346-54.
Rizvi M, Pathak D, Freedman JE, Chakrabarti S. CD40-CD40 ligand interactions in oxidative stress, inflammation and vascular disease. Trends in Molecular Medicine, 2008;14:530-538.
Keaney JF Jr, Lipinska I, Larson MG, Dupuis J, Freedman JE, Hamburg NM, Massaro JM, Rong J, Sutherland P, Vita JA, Vasan RS, Benjamin EJ. Clinical correlates, heritability, and genetic linkage of circulating CD40 ligand in the Framingham Offspring Study. Am Heart J. 2008;156:1003-1009.
Chakrabarti S, Rizvi M, Pathak D, Kirber MT, Freedman JE. Hypoxia Influences CD40-CD40L Mediated Inflammation in Endothelial and Monocytic Cells. Immunology Letters. Accepted for publication 12/08.
Lin E, Freedman JE, Beaulieu LM. Innate Immunity and Toll-like Receptor Antagonists: A Potential Role in the Treatment of Cardiovascular Diseases. Cardiovascular Therapeutics. 1/09; accepted for publication.
Freedman JE, Hylek E. Clopidogrel, genetics, and drug responsiveness. New England Jnl of Medicine. 2009 Jan 22;360(4):411-3.
Rex S, Beaulieu LM, Perlman DH, Vitseva O, Blair PS, McComb ME, Costello CE, Freedman JE. Immune vs. thrombotic stimulation of platelets differentially regulates signaling pathways, intracellular protein-protein interactions, and -granule release. Thrombosis and Haemostasis. 2009 Jul;102(1):97-110.
New therapies for stroke prevention in atrial fibrillation: the long road to enhanced efficacy. Freedman JE, Gersh BJ. Circulation. 2009 Sep 22;120(12):1024-6
NFkappaB regulation of platelet function: no nucleus, no genes, no problem? Beaulieu LM, Freedman JE. J Thromb Haemost. 2009 Aug;7(8):1329-32.
M118, a novel low-molecular weight heparin with decreased polydispersity leads to enhanced anticoagulant activity and thrombotic occlusion in ApoE knockout mice. Chakrabarti S, Beaulieu LM, Reyelt LA, Iafrati MD, Freedman JE. J Thromb Thrombolysis. 2009 Apr 28.